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Abstract
Adamantinomatous craniopharyngiomas (ACPs) are clinically challenging tumours, the majority of which have activat-
ing mutations in CTNNB1. They are histologically complex, showing cystic and solid components, the latter comprised of 
different morphological cell types (e.g. β-catenin-accumulating cluster cells and palisading epithelium), surrounded by a 
florid glial reaction with immune cells. Here, we have carried out RNA sequencing on 18 ACP samples and integrated these 
data with an existing ACP transcriptomic dataset. No studies so far have examined the patterns of gene expression within 
the different cellular compartments of the tumour. To achieve this goal, we have combined laser capture microdissection 
with computational analyses to reveal groups of genes that are associated with either epithelial tumour cells (clusters and 
palisading epithelium), glial tissue or immune infiltrate. We use these human ACP molecular signatures and RNA-Seq data 
from two ACP mouse models to reveal that cell clusters are molecularly analogous to the enamel knot, a critical signalling 
centre controlling normal tooth morphogenesis. Supporting this finding, we show that human cluster cells express high 
levels of several members of the FGF, TGFB and BMP families of secreted factors, which signal to neighbouring cells as 
evidenced by immunostaining against the phosphorylated proteins pERK1/2, pSMAD3 and pSMAD1/5/9 in both human 
and mouse ACP. We reveal that inhibiting the MAPK/ERK pathway with trametinib, a clinically approved MEK inhibitor, 
results in reduced proliferation and increased apoptosis in explant cultures of human and mouse ACP. Finally, we analyse a 
prominent molecular signature in the glial reactive tissue to characterise the inflammatory microenvironment and uncover 
the activation of inflammasomes in human ACP. We validate these results by immunostaining against immune cell markers, 
cytokine ELISA and proteome analysis in both solid tumour and cystic fluid from ACP patients. Our data support a new 
molecular paradigm for understanding ACP tumorigenesis as an aberrant mimic of natural tooth development and opens 
new therapeutic opportunities by revealing the activation of the MAPK/ERK and inflammasome pathways in human ACP.
Keywords Craniopharyngioma · Odontogenesis · Inflammasome · IL1-β · MAPK/ERK pathway · Trametinib · Paracrine 
signalling
Introduction
Adamantinomatous craniopharyngioma (ACP) is the 
most common tumour of the sellar region in children 
[39]. Despite being cytologically benign, ACPs display 
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clinically aggressive behaviour such as destruction of 
the pituitary gland and invasion of the hypothalamus and 
visual pathways, altogether leading to chronic severe mor-
bidity and increased mortality during long-term follow-up 
[41, 43].
ACPs are histologically complex tumours with variable 
cystic, calcified and solid components. They frequently 
invade adjacent tissues with infiltrating finger-like struc-
tures surrounded by a florid glial and inflammatory reac-
tive tissue [39]. A pathognomonic feature of ACP is the 
presence of anuclear ghost cells, also known as “wet 
keratin”, while other common features include calcifi-
cation and cholesterol clefts [35, 39]. The majority of 
ACPs have somatic activating mutations in CTNNB1, the 
gene encoding β-catenin [8, 10, 31, 35, 50]. However, 
nucleo-cytoplasmic accumulation of β-catenin is limited 
to only a small proportion of cells, often correlating with 
epithelial whorl-like structures (referred to as β-catenin-
accumulating cell clusters), or in single cells throughout 
the tumour [8, 23, 25, 31, 41]. As expected, these regions 
correlate with WNT pathway activation, evidenced by the 
expression of pathway target genes (e.g. AXIN2 and LEF1) 
[25, 51]. In contrast, in other histological compartments 
such as the palisading epithelium or stellate reticulum, 
β-catenin expression is limited to the cell membrane and 
activation of the WNT pathway is less pronounced [25]. 
The similarities between ACP and both normal tooth 
development and odontogenic tumours have been recog-
nised for decades, on the basis of their comparable histopa-
thology and co-expression of enamel proteins, proteinases 
and some keratins, as well as the occasional identification 
of fully formed teeth in ACP [6, 42, 49]. However, the 
molecular mechanisms underlying these commonalities 
are not well understood [7, 10, 19, 29, 32, 42, 45, 51, 54].
Insight into the functional significance of the β-catenin-
accumulating cell clusters has been provided by studies con-
ducted in murine ACP models, where a degradation-resistant 
(activated) form of β-catenin is expressed in either Rathke’s 
pouch derivatives (Hesx1Cre/+/Ctnnb1lox(ex3)/+ mouse line; 
ACP embryonic model) or Sox2-expressing adult pituitary 
stem cells (Sox2CreERT2/+/Ctnnb1lox(ex3)/+ mouse line; ACP 
inducible model). Evidence gathered from both models sug-
gests these clusters act in a paracrine manner, driving tumour 
growth and/or invasion into surrounding tissues through the 
secretion of a wide range of factors (e.g. SHH, FGFs, BMPs, 
TGFB1; as well as pro-inflammatory mediators such IL1, 
IL6 and other CXC and CC chemokines) [1, 2, 14, 17, 41, 
53]. This hypothesis is consistent with their location at the 
leading edge of tissue invasion in human tumours [3, 9, 53]. 
These findings have raised interest in discovering therapeutic 
approaches targeting these clusters and highlighted a need to 
better understand the pathways and cellular processes active 
both within clusters and the responding tissues.
Two recent publications have analysed mRNA expres-
sion microarray profiles of ACPs, comparing either with 
other tumour types and control tissues, or with the BRAF 
mutation-driven papillary craniopharyngioma (PCP) 
subtype. These studies have highlighted the differences 
between ACP and PCP and identified a number of poten-
tial therapeutic targets using differential expression analy-
sis, many of these previously anticipated by studies using 
the murine models [21, 26]. However, correlation between 
dysregulated gene pathways in human ACP and tumour 
architecture has been limited to the analyses of specific 
proteins by immunostaining. Revealing which pathways 
are dysregulated in specific tumour cellular compartments 
is important to increase our understanding of the patho-
genesis of human ACP. Additionally, it is a necessary step 
to determine which cells are likely to be susceptible to spe-
cific targeted therapies, helping predict possible outcomes. 
For instance, pancreatic ductal cell carcinoma (PDCA) 
epithelial cells secrete SHH and activate the pathway in 
the tumours, but its targeted inhibition in mouse models 
and patients causes disruption of the host-derived stroma 
with little effect on the cancer epithelial cells, resulting 
in rapid disease progression and increased aggressiveness 
[36, 46].
In this manuscript, we have performed a comprehen-
sive gene expression study of 18 human ACPs combin-
ing whole-tumour RNA-Seq with transcriptomics of laser 
capture microdissected tumour cellular components to 
reveal the molecular signatures of specific tumour cell 
compartments. We complement this gene expression 
study with proteome analysis and ELISA of both tumour 
and cystic fluid from ACP patients. Our data provide a 
molecular rationale for the resemblance of ACP and tooth 
development and highlight a complex signalling cascade 
orchestrated by the cluster cells. Of clinical relevance, 
we identify the MAPK/ERK pathway and inflammasome 
signalling as potentially targetable pathways and provide 
preclinical evidence supporting the use of MEK inhibitors 
against human ACP.
Materials and methods
Human tumour and pituitary samples
Anonymised archival frozen and formalin-fixed paraffin-
embedded (FFPE) specimens of ACP and non-functioning 
pituitary adenoma (NFPA) were identified in the local 
pathology archive, through the Childhood’s Cancer and 
Leukaemia Group Tissue Bank, Brain UK and from col-
laborators. Fetal pituitary tissue (19 weeks corrected gesta-
tional age) was accessed through the Human Developmental 
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Biology Resource (HDBR). Further details can be found in 
Suppl. Materials and Methods (Online Resource 1).
Laser capture microdissection (LCM)
Two cases (JA004, JA029) were used for LCM because they 
contained easily definable histological features (clusters, pal-
isading epithelium and glial reaction) and cryopreserved tis-
sue of sufficient quality was available. Further details can be 
found in Suppl. Materials and Methods (Online Resource 1).
RNA sequencing
For human ACP samples sequencing was performed by UCL 
Genomics. Murine ACP samples were sequenced by the 
Oxford Wellcome Trust Centre for Human Genetics. Fur-
ther details can be found in Suppl. Materials and Methods 
(Online Resource 1).
Immunostaining of histological sections
Immunohistochemistry and immunofluorescence staining 
was performed as previously described [1, 14, 26]. Anti-
body details can be found in Suppl. Materials and Methods 
(Online Resource 1).
Ex vivo culture of mouse and human tumours
Ex vivo culture of neoplastic pituitaries was performed as 
described [17] in the presence of either trametinib at 2 or 
20 nM (Mekinist) or DMSO (vehicle control). Histological 
analysis was performed after 18 h. Small pieces of human 
ACP (around 1–2 mm3) were cultured in identical condi-
tions. The proportion of Ki67 positive and cleaved cas-
pase-3 cells in the ex vivo culture experiments was calcu-
lated as an index out of the total DAPI-stained nuclei. Over 
150,000 DAPI nuclei were counted from six histological 
sections per pituitary in a total of six neoplastic pituitaries. 
Three human tumours were used in the ex vivo experiments 
and the Ki-67 and cleaved caspase-3 index calculated as 
described above from four histological sections per tumour 
(over 192,000 cells counted).
Cytokine multiplex ELISA
Levels of TNF-α, IFN-γ, IL-1β, IL-6. IL-8, IL-10 and 
IL-18 were measured in ACP tumour and ACP cystic fluid 
using a Meso Scale Discovery (MSD) multiplex kit (Meso 
Scale Diagnostics) as per the manufacturer’s instruc-
tions. For solid tumours, protein lysates were extracted 
from pieces of fresh frozen ACP. Briefly, 6- to 28-mg 
samples were placed in 250 μl of lysis buffer (150 mM 
NaCl, 20 mM Tris pH 7.5, 1 mM EDTA, 1 mM EGTA, 
1% Triton, with Protease Inhibitor (Roche), 1 mM sodium 
orthovanadate and 25 mM sodium fluoride). Samples were 
sonicated on ice and left for 30 min at 4 °C, followed 
by centrifugation at 20,000g for 10 min and collection 
of supernatant. Protein concentrations were quantified by 
Bradford assay. Cytokine levels were normalised against 
total protein added to the ELISA.
Results
Samples and RNA sequencing data analysis
A total of 18 primary ACP samples and six control tissues 
(three fetal pituitaries and three non-functioning pituitary 
adenomas, NFPA) were analysed by RNA-Seq. We chose 
fetal pituitaries as control sample because ACP is thought 
to derive from remnants of Rathke’s pouch, the primordium 
of the anterior pituitary. RNA quality from post-mortem 
normal adult pituitaries was inadequate for RNA sequenc-
ing. As NFPA are tumours containing cells similar to the 
normal adult pituitary and are known to cluster with nor-
mal pituitary tissue on expression analysis [21], these were 
also used as controls. Activating mutations in exon 3 of 
CTNNB1 were identified in all of the ACP cases, except for 
JA011 and JA005, with a mutation allele frequency ranging 
between 6% and 48% [Suppl. Table 1 (Online Resource 2)]. 
Targeted DNA sequencing of an adjacent frozen sample of 
case JA011 revealed a CTNNB1 p.Gly34Arg mutation with 
a variant allele frequency of 4.7% [Suppl. Table 1 (Online 
Resource 2)]. There was insufficient material to perform tar-
geted sequencing on JA005. Immunohistochemistry against 
β-catenin in case JA005 failed to identify cells, which accu-
mulated the protein and analysis of RNA data did not reveal 
mutations in other CTNNB1 exons [Suppl. Table 1 (Online 
Resource 2)]. The allelic frequencies of mutant CTNNB1 sig-
nificantly correlated with the estimated histological tumour 
content (r = 0.88, p = 6.61 × 10−8) and were consistent with 
the presence of a heterozygous mutation within all tumour 
cells [Suppl. Table 1 (Online Resource 2); Fig. 1b]. Princi-
pal component analysis (PCA) and clustering confirmed the 
separation of tumours (including JA005 and JA011) from 
controls [Fig. 1c; Suppl. Fig. 1a (Online Resource 3)]. Dif-
ferential gene expression revealed that a total of 6099 genes 
were significantly expressed at higher levels in tumours 
versus controls, while 5211 genes were higher in controls 
versus tumours (adjusted p value < 0.1) [Suppl. Table 2a 
(Online Resource 4)]. The genes and ontology pathways 
found to be dysregulated in our dataset are consistent with 
published RNA and immunohistochemical expression stud-
ies and demonstrate that these results are robust and bio-
logically meaningful [Fig. 1d; Suppl. Table 2a, b (Online 
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Fig. 1  Bioinformatics analysis of gene expression profiling of human 
ACP whole tumours identifies modules of genes potentially associ-
ated with specific tumour cell compartments. a Representative histol-
ogy of ACP samples showing and areas of tumour (T), reactive glial 
tissue (G), wet keratin/ghost cells (WK), epithelial whorls (C) (epi-
thelial whorls referred to in this paper as clusters), palisading epithe-
lium (PE) and stellate reticulum (SR). Immunohistochemistry using 
antibodies against β-catenin (β-cat) on case JA029 showing clusters 
of cells with nuclear-cytoplasmic accumulation. Scale bars 400  μm 
(top left panel), 100 μm (other three panels). b Scatterplot revealing 
a significant correlation between CTNNB1 mutation frequency and 
histologically assessed tumour content. # case JA011; * case JA005; 
controls: fetal pituitaries and NFPA tissues. See Suppl. Table  1 
(Online Resource 2) for sample details. c Principal component analy-
sis plot showing the separation between adamantinomatous crani-
opharyngioma (ACP), non-functioning pituitary adenoma (NFPA) 
and control fetal pituitary tissues (fetal). d Bar plot of selected statis-
tically significant and differentially expressed genes, as assessed by 
DESeq2, in ACP tumours compared with control fetal tissue. Higher 
than 0 means higher expression in ACP and lower than 0 means 
higher in control tissue. The most up-regulated genes in ACP tumours 
are keratins. Other up-regulated genes include WNTs and WNT 
pathway targets (e.g. NOTUM, AXIN2, LEF1), genes known to be 
expressed in ACP (e.g. FGFs, BMPs) and previously suggested thera-
peutic targets (SHH, MMP12, MMP9, EGFR). Pituitary transcrip-
tion factors (LHX3, POU1F1) and pituitary hormones (e.g. FSHB, 
GH1, TSHB) are up-regulated in controls. See Suppl. Table 3 (Online 
Resource 5) for details. Error bars = 1 standard error, *** adjusted p 
value < 1 × 10−9. e Multidimensional scaling plot of expression pat-
terns of the 5000 most differentially expressed genes included in the 
weighted gene co-expression network analysis (WGCNA) analysis. 
The colour of each gene indicates it membership to a co-expressed 
gene expression module. f Heatmap of correlations between each 
module’s gene expression profile and phenotypic information. Scale 
bar indicate r value − 1 to + 1. For instance, the brown module shows 
a strong correlation with tumour content and mutational frequency, 
whilst the blue module correlates with the presence of glial reactive 
tissue and GFAP
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Resource 4) and Suppl. Table 3 (Online Resource 5)] [1, 2, 
10, 16, 21, 24].
Computational modular analysis 
and transcriptomics of laser capture microdissected 
tumour cells reveal the molecular signatures 
of specific cellular compartments
Next, we aimed to further dissect the molecular signatures 
obtained from the RNA-Seq data and establish if these cor-
related with particular tumour characteristics including 
diagnosis, percentage of tumour content, CTNNB1 muta-
tion allele frequency and the presence of specific histologi-
cal features. Weighted gene co-expression network analysis 
(WGCNA) was used to describe the correlation patterns 
among genes across samples, resulting in the identification 
of 12 distinct patterns of gene expression (modules), which 
were assigned a colour identifier (Fig. 1e). Three major dis-
tinct patterns of gene expression across the samples were 
determined: (1) the brown module, consisting of genes relat-
ing to epithelial differentiation and whose expression cor-
related with percentage tumour content and CTNNB1 muta-
tion allele frequency [Fig. 1f; Suppl. Table 4a, e (Online 
Resource 6); Suppl. Fig. 2a (Online Resource 3)]; (2) the 
blue and turquoise modules, containing genes involved in 
nervous system development, whose expression correlated 
with the presence of reactive glial tissue [Fig. 1f; Suppl. 
Table 4a, j, l (Online Resource 6); Suppl. Fig. 3a, b (Online 
Resource 3)]; (3) the magenta module, including inflamma-
tion-related genes whose expression correlated with immune 
cell markers such as CD14 [Fig. 1f; Suppl. Table 4a, k 
(online Resource 6); Suppl. Fig. 2d (Online Resource 3)]. 
Further details of other identified modules are presented 
in Suppl. Results (Online Resource 1), Suppl. Figs. 2–4 
(Online Resource 3) and Suppl. Table 4 (Online Resource 
6). WGCNA of the human ACP microarray data published 
by Gump et al. [21] also showed moderate preservation of 
the major modules with our datasets [Suppl. Results (Online 
Resource 1)], suggesting that the molecular signatures of 
the main cellular types within ACP samples (i.e. tumour 
epithelium, reactive glial tissue and inflammatory infiltrate) 
may be contained in specific modules.
To validate the WGCNA results, we profiled specific cel-
lular compartments of human ACP, through the isolation 
of cluster cells, palisading epithelium and reactive glial tis-
sue by laser capture microdissection (LCM) (Fig. 2a, b). 
As a result of the rarity of suitable tissue, we performed 
this experiment using only two human ACP tumours, none-
theless RNA-Seq data was robust and representative of the 
isolated cell compartments. For instance, gene set enrich-
ment analysis (GSEA) confirmed the enrichment of a WNT 
signalling expression signature in tumour tissue (i.e. clusters 
plus palisading epithelium, PE) when compared with glial 
reactive tissue (normalised enrichment score (NES) = 1.52, 
false discovery rate (FDR) = 0.106), whilst an inflammatory 
response signature was associated with the glial reactive tis-
sue (NES = − 1.87, FDR = 0.03) (Fig. 2c). Enrichment for 
WNT signalling was stronger in the clusters relative to both 
PE (NES = 1.81, FDR = 0.013) and glial tissue (NES = 1.82, 
FDR = 0.004), in agreement with the higher expression of 
WNT target genes in cluster cells (e.g. AXIN2, LEF1 and 
NOTUM) (Fig. 2c) [14]. A full list of the differentially 
expressed genes between clusters, palisading epithelium and 
reactive glia is shown in Suppl. Table 2c–e (Online Resource 
4).
By systematically comparing the molecular signatures 
obtained from these profiling experiments with the mod-
ules previously described, we confirmed that the brown 
module genes were enriched in the signature of tumour 
cell compartments (i.e. cluster cells and palisading epi-
thelium) (NES = 2.24, FDR < 0.001) (Fig. 2d). In contrast, 
both the blue and turquoise module genes were predomi-
nantly expressed by reactive glia (blue, NES = − 3.36; tur-
quoise, NES = − 3.06; FDR < 0.001) (Fig. 2d). Supporting 
the notion that these modules represent specific signatures, 
genes known to be expressed in tumour epithelium, such as 
WNT targets (e.g. AXIN2, NOTUM), FGF3 and BMP4 were 
contained in the brown module [Suppl. Table 4a (Online 
Resource 6)]. Likewise, genes known to be expressed in 
the glial reactive tissue, such as GFAP, S100B and NKX2.2 
were contained in the blue and turquoise modules [Suppl. 
Table 4a (Online Resource 6)]. Of interest, the three genes 
with the strongest brown module membership score (a meas-
ure of the degree of co-expression) were TP63, APCDD1L 
and BCL11B [Suppl. Table 3a (Online Resource 6)]. TP63 
has previously been shown to be expressed in the tumour 
cells in human ACP [11], but APCDD1L and BCL11B have 
not been implicated in ACP. Consistently, immunofluores-
cence of ACP histological sections revealed the expression 
of BCL11B and TP63 exclusively in tumour cell compart-
ments, including clusters, palisading epithelium and stel-
late reticulum, but not within surrounding reactive tissue 
(Fig. 2e). Similarly, immunofluorescence revealed expres-
sion of APCDD1L mostly in the cluster cells with no expres-
sion in the vast majority of the glial tissue except for cells 
adjacent to the tumour cells [Suppl. Fig. 5 (Online Resource 
3)]. This is in agreement with the differential expression 
analysis of the laser capture microdissection dataset show-
ing that APCDD1L is highly expressed in the clusters ver-
sus glial reactive tissue [40.46-fold, adjusted p value = 0.12; 
Suppl. Table 2e (Online Resource 4)]. Plotting of normalised 
expression levels confirmed the relationship of these brown 
module genes with CTNNB1 mutation allele frequency, fur-
ther supporting that expression of these genes is enriched 
within the tumour cells (r = 0.83, 0.95, 0.96 respectively for 
each gene, p < 1 × 10−5) [Suppl. Fig. 6 (Online Resource 3)]. 
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Fig. 2  Gene profiling of laser capture microdissected tumour cells 
confirms the WGCNA, identifying modules associated with tumour 
cell compartments and revealing novel ACP genes. a Scheme of the 
experimental approach. Histological sections of tumour samples 
JA004 and JA029 were subjected to laser capture microdissection 
(LCM) to isolate β-catenin-accumulating cell clusters (C), palisad-
ing epithelium (PE) and glial reactive tissue (G). Biological dupli-
cates were performed for clusters and palisading epithelium in case 
JA004. RNA was purified from each of these tumour cell compart-
ments, amplified and sequenced. b Principal component analysis 
reveals grouping of the data from laser capture microdissected sam-
ples. c Gene set enrichment analysis revealing the enrichment of an 
inflammatory signature in microdissected glial reactive tissue relative 
to tumour tissue (i.e. genes included in clusters plus palisading epi-
thelium), whilst a WNT signalling expression signature is associated 
with the microdissected tumour tissue. Enrichment for WNT signal-
ling was stronger in the clusters relative to both PE and glial tissue. 
d Gene set enrichment analysis showing the enrichment of the brown 
module genes with a signature of tumour cell compartments (i.e. genes 
including in cluster cells plus palisading epithelium). In contrast, both 
the blue and turquoise module genes are predominantly expressed by 
reactive glia. e Double immunofluorescence staining revealing the 
expression of BCL11B and TP63 in the epithelial components of the 
tumour, including palisading epithelium (PE) and β-catenin accumu-
lating clusters (C), but not in reactive glial tissue (G). NES normalised 
enrichment score, FDR false discovery rate. Scale bars 100 μm
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These datasets represent a useful resource for the identifica-
tion of novel genes specifically expressed or highly enriched 
within particular human ACP cell compartments. Together, 
these studies have revealed the molecular signatures of the 
tumour epithelium (i.e. cluster cells and palisading epithe-
lium) and glial reactive tissue (astrocytes and immune cells).
Human ACP clusters are molecularly analogous 
to the enamel knot and activate a transcriptional 
programme resembling odontogenesis
We then used the RNA data from profiling whole tumours 
and compartment-specific molecular signatures obtained by 
LCM to explore the relationship between ACP and odon-
togenesis at a molecular level. The brown module genes, 
enriched in the signature of tumour cell compartments, con-
tained genes related to odontogenesis [Suppl. Table 4a, e 
(Online Resource 6]. GSEA was performed using sets of 
genes experimentally confirmed to be expressed in specific 
cell types during tooth development in human and other spe-
cies [30]. These studies revealed that, compared to control 
tissues (fetal pituitary and NFPA), human ACP tumours 
(based on whole-tumour RNA datasets) were enriched 
for genes expressed in both ameloblasts (NES = 2.57, 
FDR < 0.001) and their precursors, the inner enamel epi-
thelium (NES = 2.79, FDR < 0.001; dataset from all stages 
of inner epithelium development (Fig. 3a) [30]. The expres-
sion of ameloblast transcription factors (e.g. BCL11B, 
MSX2), enamel genes (ENAM, AMELX, AMELY, AMBN) 
and proteinases (MMP20, KLK4) was significantly higher in 
human ACP compared with control tissues [Fig. 3b; Suppl. 
Table 5 (Online Resource 7)]. In contrast, genes specifically 
expressed in dental mesenchyme-derived odontoblasts were 
not up-regulated in human ACP (e.g. MSX1, DSPP) [Fig. 3b; 
Suppl. Table 5 (Online Resource 7)].
By comparing the molecular signatures of specific tumour 
compartments obtained by LCM with curated gene sets 
derived from distinct cell types present during tooth devel-
opment [30], we identified molecular similarities between 
the ACP β-catenin-accumulating cell clusters and the 
enamel knot, a critical signalling centre within the develop-
ing tooth [28, 55]. Gene set enrichment analysis revealed a 
significant enrichment of the enamel knot gene signature in 
human cluster cells when compared with either palisading 
epithelium (NES = 1.90, FDR = 0.004) or to reactive glial 
tissue (NES = 1.79, FDR = 0.01) (Fig. 3c). Enamel knot sig-
nals act on the inner enamel epithelium at the cap stage of 
tooth development to control proliferation and tooth mor-
phogenesis, and we identified a strong enrichment between 
palisading epithelium and cap-stage enamel epithelium [30], 
suggesting that palisading and enamel epithelium may be 
equivalent structures (NES = − 1.69, FDR = 0.008) (Fig. 3c).
We validated these findings further by immunofluores-
cence against p21/CDKN1A, a marker of the enamel knot, 
which showed specific signal mostly restricted to human 
ACP clusters (n = 8 tumour samples; Fig.  3d), consist-
ent with previous reports [10, 17]. In addition, the ectod-
ysplasin receptor (EDAR), whose signalling pathway has 
been strongly implicated in enamel knot formation but not 
previously studied in ACP [55, 56], was highly expressed 
in ACP tumours compared with controls (467.88-fold; 
adjusted p value = 1.37E−29) and in β-catenin clusters 
relative to palisading epithelium (10.85-fold; adjusted p 
value = 0.0001) or glial reactive tissue (357.05-fold; adjusted 
p value = 9.77E−05) [Suppl. Table 2a, d, e (Online Resource 
4)]. Immunofluorescence confirmed the expression of EDAR 
in human cluster cells and its absence in the glial reactive 
tissue, further confirming similarities between ACP clusters 
and the enamel knot (n = 5 human tumours; Fig. 3d).
To test further these findings, we performed RNA-Seq 
on three Hesx1Cre/+/Ctnnb1lox(ex3)/+ neoplastic and three 
control pituitaries at postnatal day 1 (P1). As in human 
ACP, GSEA also confirmed greater expression of inner 
enamel epithelium (cap stage) (NES = 2.61, FDR < 0.001) 
and ameloblast (NES = 2.38, FDR < 0.001) genes in Hes-
x1Cre/+/Ctnnb1lox(ex3)/+ neoplastic pituitaries at P1 com-
pared with wild-type controls, further highlighting the 
molecular relationship between mouse ACP and tooth 
development [Fig. 3e; Suppl. Table 2f (Online Resource 
4)]. Mouse ACP also contains β-catenin-accumulating 
cell clusters, and we have previously characterised their 
expression profiles in both the Hesx1Cre/+/Ctnnb1lox(ex3)/+ 
embryonic and the Sox2CreERT2/+/Ctnnb1lox(ex3)/+ inducible 
mouse models of ACP [1, 17]. GSEA revealed a molecu-
lar signature of the enamel knot in the clusters from both 
of these mouse models (embryonic model, NES = 1.90, 
FDR = 0.003; inducible model NES = 2.44, FDR < 0.001) 
(Fig. 3f). Expression of p21 has recently been reported to 
be enriched in the clusters in mouse ACP [17], but EDAR 
immunostaining was inconclusive, possibly because the 
antibody does not recognise mouse EDAR. Together, 
these results reveal molecular analogies shared between 
ACP β-catenin-accumulating clusters with the enamel 
knot and the palisading epithelium with the inner enamel 
epithelium.
Cell clusters orchestrate paracrine signalling 
within human and murine ACP
The molecular similarities between human clusters and the 
enamel knot prompted us to explore further whether the 
clusters may also act as signalling centres in human ACP 
tumours. In agreement with this notion, our RNA profiling 
revealed that human ACP clusters expressed high levels of 
members of the FGF, BMP and WNT families of secreted 
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Fig. 3  ACP and developing mammalian tooth share common molecu-
lar signatures. a Gene set enrichment plots showing that ACP tumours 
are enriched for genes expressed by ameloblasts and inner enamel 
epithelium. Results obtained from using the RNA dataset from pro-
filing whole ACP tumours. b Expression of relevant ameloblast-
related genes is significantly expressed at higher levels in whole ACP 
tumours compared with control tissues (fetal pituitary and NFPA). 
See Suppl. Table  5 (Online Resource 7) for details (*** adjusted p 
value < 1 × 10−7, * adjusted p value = 0.028). c Gene set enrichment 
plots showing that the cluster cells are enriched for genes expressed 
in the enamel knot whilst palisading epithelium shows a signature of 
inner enamel epithelia at cap stage. Results obtained from using the 
RNA dataset from profiling microdissected ACP compartments. d 
Double immunofluorescent staining reveals the co-expression of p21/
CDKN1A and EDAR, two enamel knot markers, in the β-catenin-
accumulating clusters. e Gene set enrichment analysis showing that 
both the inner enamel epithelium and ameloblast gene signatures are 
enriched in the embryonic mouse ACP model compared with wild-
type controls (WT). f Enrichment plots confirming that mouse clusters 
from both the embryonic and inducible ACP mouse models show a 
molecular signature of the enamel knot. NES normalised enrichment 
score, FDR false discovery rate. Scale bars 100 μm
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factors compared with either palisading epithelium or reac-
tive glia [Suppl. Fig. 7 (Online Resource 3); Suppl. Table 2d, 
e (Online Resource 4)]. SHH was also highly expressed by 
the cluster cells (Suppl. Fig. 7a), as previously shown [1]. 
The activation of the WNT pathway in human ACP has been 
well documented, and we identified the expression of sev-
eral WNT ligands (e.g. WNT4, WNT5A, WNT6, WNT7A, 
WNT10A, WNT10B and WNT16) in the clusters relative to 
the palisading epithelium or glial reactive tissue [Suppl. 
Fig. 7b (Online Resource 3); Suppl. Table 2d, e (Online 
Resource 4); adjusted p value ≤ 0.03]. To reveal the cells 
responding to FGF, TGFβ and BMP factors, we analysed the 
expression of the ligands and their receptors in our human 
RNA-Seq datasets and performed immunofluorescence 
against downstream signalling effectors indicating pathway 
activation.
FGFR1–3 were broadly expressed across tumour and 
glial cells and not differentially expressed between compart-
ments [Suppl. Fig. 7b (Online Resource 3); Suppl. Table 2d, 
e (Online Resource 4)]. The ligands FGF3, FGF4, FGF9, 
FGF12, FGF13, FGF18 and FGF19 were highly expressed 
in the clusters relative to the palisading epithelium or the 
glial reactive tissue [adjusted p value ≤ 0.1; Suppl. Fig. 7a, 
b (Online Resource 3); Suppl. Table 2d, e (Online Resource 
4)]. Downstream activation of the MAPK/ERK pathway, as 
evidenced by phosphorylation of ERK1/2, was identified by 
immunohistochemistry and immunofluorescence within the 
palisading epithelium around the clusters and neighbouring 
reactive tissue, but no positive signal was observed in the 
clusters themselves (Fig. 4a, b, d). Particularly prominent 
staining was detected at the leading edge of tissue invasion 
(Fig. 4a). Areas of palisading epithelium around the clus-
ters were often enriched for the proliferation marker Ki67 
(Fig. 4c), concurrent with elevated pERK1/2+ve staining 
(Fig.  4b). Double immunofluorescence of three human 
ACP samples revealed a variable degree of co-localisation 
between Ki67 and pERK1/2 expression (Fig. 4d) (tumour 1: 
80%, 45 co-expressing cells out of 56 Ki67+ve cells; tumour 
2: 44%, 26 co-expressing/59 Ki67+ve cells; tumour 3: 15%, 
5 co-expressing/33 Ki67+ve cells).
BMP4 and BMP8A were highly expressed by clus-
ters (adjusted p value ≤ 0.001) and BMPR1A and BMPR2 
were expressed across all cell types, whist BMPR1B was 
highly expressed in the glial reactive tissue (adjusted p 
value = 0.00011) [Suppl. Fig.  7b (Online Resource 3); 
Suppl. Table 2d, e (Online Resource 4)]. Activation of the 
pathway, as evidenced by immunofluorescence staining 
against phosphorylated SMAD1/5/9 was widely present 
in tumour cells, particularly in proximity to the clusters, 
but was absent from the palisading epithelium (Fig. 4f). 
Other members of the TGF superfamily of secreted factors, 
such as TGFB1-3, as well as their receptors were broadly 
expressed across all tumour compartments, although TGFB1 
appeared non-significantly elevated in clusters relative to 
both PE (4.9-fold, unadjusted p value = 0.08; adjusted p 
value not assessed because of inadequate read numbers) 
and glial tissue (9.5-fold, adjusted p value = 0.37) [Suppl. 
Fig. 7a, b (Online Resource 3); Suppl. Table 2d, e (Online 
Resource 4)]. Double immunofluorescence against β-catenin 
and phospho-SMAD3 revealed the activation of the TGFβ 
pathway in tumour cells and reactive tissue. Increased sig-
nal was apparent within areas of reactive tissue closest to 
tumour cells (Fig. 4e).
We have previously shown that murine clusters in the 
Hesx1Cre/+/Ctnnb1lox(ex3)/+ embryonic model of ACP also 
express several genes of the FGF, TGFβ and BMP fami-
lies [1], but the activation of these pathways has not been 
demonstrated so far. Immunofluorescent staining revealed 
strong expression of p-ERK1/2 in cells directly surround-
ing the β-catenin-accumulating clusters, which displayed 
no positive staining themselves (Fig. 5a). p-SMAD3 and 
p-SMAD1/5/9 staining was mostly observed in cells near 
the clusters, with some cluster cells showing weak staining 
(Fig. 5b, c). These analyses are consistent with the hypoth-
esis that human and murine clusters act as signalling centres 
through the expression of multiple ligands that activate the 
SHH, WNT, MAPK/ERK, TGFβ and BMP signalling path-
ways in neighbouring cells.
Preclinical studies provide support for an important 
role of the MAPK/ERK pathway in the pathogenesis 
of both human and mouse ACP
To further understand the role of the MAPK/ERK pathway 
in human ACP and to test its potential as a therapeutic tar-
get, we targeted this pathway using trametinib, a specific 
MEK inhibitor that has shown promising results in MAPK/
ERK-driven solid tumours [34, 48] and currently being 
trialled in children and adolescents with a variety of solid 
tumours (NIH-NCI clinical trial: NCT02124772).
The neoplastic pituitaries of the Hesx1Cre/+/Ctnnb1lox(ex3)/+ 
mice at postnatal day 1 (P1) contain well-defined β-catenin-
accumulating clusters. To test the effects of trametinib in 
the mouse model, we cultured neoplastic pituitaries at P1 
in the presence or absence of 2 and 20 nM trametinib for 
18 h (n = 6 pituitaries). P1 neoplastic pituitaries resem-
ble human ACP more closely than older stages of murine 
tumour development at both the histological and molecular 
levels [4, 17, 40]. Immunofluorescence revealed an obvi-
ous decrease in p-ERK1/2 immunofluorescence within the 
neoplastic pituitaries upon trametinib treatment with both 
concentrations, which was more apparent at 20 nM, dem-
onstrating the successful inhibition of the MAPK/ERK 
pathway (Fig. 6a). Assessment of proliferation revealed a 
significant reduction in the Ki67 proliferation index between 
the 20 nM trametinib-treated and vehicle control groups 
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Fig. 4  Identification of the activation of the MAPK/ERK, TGFB and 
BMP signalling pathways in human ACP. a Immunohistochemistry 
revealing the expression of phosphorylated ERK1/2 (pERK1/2), a 
read out of active MAPK/ERK pathway, at the tips of the invading 
tumour epithelium (palisading epithelium, arrows in a, a‴ and a″″) 
and within reactive glial tissue (G; arrows in a″). b Double immu-
nofluorescent staining showing pERK1/2 expression in the palisad-
ing epithelium (PE) around the β-catenin accumulating clusters (C), 
which express several activating ligands of the MAPK/ERK path-
way (see main text for details). Note that cells within the reactive 
glial tissue (G) are also pERK1/2 positive. c Double immunofluo-
rescence revealing abundant Ki67+ve cells in the palisading epithe-
lium close to clusters. d Double immunofluorescence showing Ki67 
and pERK1/2 co-expression within the palisading epithelium (PE). 
e Double immunofluorescence showing pSMAD3 staining, indicat-
ing activation of TGFβ signalling, in both tumour and reactive glia, 
with strongest signal in reactive tissue adjacent to tumour epithe-
lia (arrowhead). Double immunofluorescence reveals pSMAD1/5/9 
staining, indicating BMP signalling in cells within and adjacent to 
the β-catenin-accumulating clusters (C). Note the absence of stain-
ing in the palisading epithelium (PE). Scale bars: a–a″″ 200 μm; b–f 
100 μm
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(vehicle, 11.6% ± 1.10; 2  nM trametinib, 10.7% ± 1.34; 
20 nM trametinib, 9.17% ± 1.27; mean ± standard devia-
tion; Kruskal–Wallis test followed by Dunn’s multiple 
comparison test; vehicle vs 2 nM p = 0.2438; vehicle vs 
20 nM p = 0.00018) (Fig. 6b). Likewise, both trametinib 
treatments resulted in a dose-dependent significant increase 
in active caspase-3 immunofluorescence, a marker of apop-
tosis (vehicle, 2.88% ± 1.08; 2 nM trametinib, 5.15% ± 2.23; 
20 nM trametinib, 10.7% ± 2.35; mean ± standard deviation; 
Kruskal–Wallis test followed by Dunn’s multiple compar-
ison test; vehicle vs 2 nM p = 0.00756; vehicle vs 20 nM 
p = 0.000002) (Fig. 6c).
Next, we performed similar ex vivo culture experiments 
using small pieces of human ACP tumours, which were cul-
tured with and without trametinib (n = 3 ACP tumours; 2 
and 20 nM trametinib or vehicle control) for 18 h. Inhibi-
tion of the MAPK/ERK pathway was revealed by a reduc-
tion of p-ERK1/2 immunofluorescence in trametinib-treated 
tumours relative to vehicle-treated controls, which was 
more accentuated at 20 nM (Fig. 7a). Immunohistochem-
istry revealed a dose-dependent, significant decrease in the 
Ki67 proliferation index upon treatment with trametinib 
(vehicle, 0.950% ± 0.140; 2 nM trametinib, 0.614% ± 0.240; 
20 nM trametinib, 0.551% ± 0.168; mean ± standard devia-
tion; Kruskal–Wallis test followed by Dunn’s multiple 
comparison test; vehicle vs 2 nM p = 0.0028; vehicle vs 
20 nM p = 0.00030). Similarly, assessment of apoptosis 
uncovered a dose-dependent increase in apoptosis, which 
reached significance at 20 nM (vehicle, 1.43% ± 0.404; 2 nM 
trametinib, 1.99% ± 0.514; 20 nM trametinib, 3.44% ± 1.56; 
mean ± standard deviation; Kruskal–Wallis test followed 
by Dunn’s multiple comparison test; vehicle vs 2  nM 
p = 0.07033; vehicle vs 20 nM p = 0.000052). Combined 
together, these preclinical studies provide preliminary evi-
dence for a potential anti-tumoural effect of trametinib on 
ACP. Specifically, we show that trametinib treatment signifi-
cantly reduces proliferation and increases apoptosis in both 
human and mouse ACP in vitro.
Cytokine profiling of tumour and cystic fluid 
suggests activation of the inflammasomes in human 
ACP
Our transcriptional analysis of whole ACP tumours exposed 
another major pattern of gene expression, the magenta mod-
ule, which correlated with immune cell markers and was 
enriched for immune system genes [Fig. 1f; Suppl. Table 4a, 
k (Online Resource 6); Suppl. Fig. 2d (Online Resource 3)]. 
Supporting this finding, immunohistochemistry against 
CD68 and CD3 revealed myeloid-derived (CD68+ve) and 
lymphoid-derived (CD3+ve) cells variably infiltrating the 
reactive glial and tumour epithelial compartments within 
human ACP (Fig. 8a). Of note, myeloid cells, as evidenced 
by immunohistochemistry for CD68 or IBA1, were fre-
quently observed in close association with the cholesterol 
clefts (Fig. 8a).
In addition, cytokine-encoding genes were highly up-
regulated in ACP whole tumours compared with controls 
[Suppl. Table 6 (Online Resource 8)]. The expression of 
IL1B, IL18 and IL10 correlated significantly with the 
immune infiltrate and inflammatory cell markers, particu-
larly CD14 and CD68 (r > 0.73, p < 1 × 10−5), as opposed 
to CTNNB1 mutation allele frequency [Fig.  8b; Suppl. 
Table 6 (Online Resource 8)]. This suggests that cytokine 
expression predominantly derived from immune rather than 
tumour cells. The presence of cytokines in the ACP tumours 
was also assessed by multiplex ELISA against IL1B, IL6, 
IL8 (CXCL8), IL10, IL18, TNF (TNFα) and IFNG (IFNγ), 
which revealed the expression of all of these but IFNG in 
protein lysates from eight human ACPs (Fig. 8c). This is 
in line with recent findings [13]. Immunohistochemistry 
against IL1B, IL6 and IL8 did not yield reliable results in 
our hands using different antibodies.
The cystic fluid of ACP has been shown to contain inflam-
matory modulators [13, 59]. To explore the protein compo-
sition in greater detail, comprehensive proteome analysis 
was completed on cystic fluid from six ACP patients [Suppl. 
Materials and Methods (Online Resource 1)]. To obtain 
greater depth in the proteome coverage, samples of fluid 
were first subjected to a combinatorial peptide bead equali-
sation [Suppl. Fig. 8a (Online Resource 3)]. In total, 461 
proteins were identified in all samples, using an FDR of 1% 
and requiring at least two unique peptides for each protein 
[Suppl. Table 7 (Online Resource 9)]. The overall proteome 
profile of all six cystic fluid samples was similar [Suppl. 
Fig. 8b (Online Resource 3)], covering an excess of five 
orders of magnitude. The most abundant proteins included 
albumin and several inflammation-associated proteins such 
as apolipoproteins, particularly APOA1 and APOA2, com-
plement system proteins and immunoglobulins [Suppl. 
Fig. 8c (Online Resource 3]. Ontology analysis revealed an 
enrichment for terms related to immune/defence response, 
inflammation and sterol metabolism [Suppl. Fig. 8d (Online 
Resource 3)]. Cytokines were not detected in the proteome 
analysis, almost certainly attributable to their very low con-
centrations. We used multiplex ELISA to demonstrate the 
presence of IL1B, IL6, IL8, IL10, IL18, TNF and IFNG 
in the cystic fluid and whole ACP tumour protein lysates 
(Fig. 8c).
The cytokine profile identified in the ACP RNA-Seq 
dataset, in particular the significantly higher expression 
of IL1A (18.1-fold), IL18 (14.8-fold), TNF (10.4-fold) 
and IL1B (7-fold) in human ACP tumours relative to con-
trols, was suggestive of inflammasome activation [Suppl. 
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Table 6 (Online Resource 8)]. Inflammasomes are innate 
danger-associated pattern recognition protein complexes 
that activate and up-regulate IL1 family members, par-
ticularly IL1B and IL18. This subsequently drives a pro-
inflammatory response through secondary expression of 
pro-inflammatory cytokines including IL6, IL8, TNF and 
chemokines (e.g. CCL2) [5, 22, 37]. Several genes encod-
ing core inflammasome components were all significantly 
expressed at higher levels in ACP tumours compared with 
control tissues, including NLRP1 (6.4-fold), NLRP3 (4.8-
fold), NLRC4 (4.8-fold), CASP1 (5-fold) and PYCARD 
(4-fold) [Suppl. Table 2a (Online Resource 4)]. Moreover, 
GSEA highlighted a significant enrichment of the IL1B 
response signature in ACP tumours using three independ-
ent datasets of genes up-regulated upon IL1B treatment 
(NES = 1.79, 2.25, 2.66, respectively; FDRs < 0.001) 
(Fig. 9a). Complementing the mRNA expression data, 
protein levels of the downstream cytokines IL6, IL8 and 
TNF correlated with the protein levels of IL1B in ACP 
cystic fluid, supporting a role of IL1B in activating the 
inflammasomes (IL6, r = 0.91, p = 0.0002; IL8, r = 0.95, 
p = 2.4 × 10−5; TNFα, r = 0.96, p = 1.41 × 10−5) (Fig. 9c).
Having shown an expression profile, at both the mRNA 
and protein levels, supportive of the activation of inflam-
masomes in human ACP, we sought to explore the simi-
larities of this molecular signature with that caused by 
other inflammasome activators. Cholesterol and other 
crystals (e.g. uric acid crystals) are established activa-
tors of inflammasomes, which mediate inflammation 
and are implicated in the pathogenesis of atherosclerosis 
and arthropathies (e.g. gout) [22, 33]. The ACP inflam-
matory cytokine profile was similar to that seen in gout, 
specifically regarding the high levels of IL1B, IL6 and 
IL18 [12]. Interestingly, we observed strong expression 
of the inflammasome-induced chemokine CCL2 in asso-
ciation with cholesterol clefts (Fig.  8a), while GSEA 
revealed a significant enrichment of an atherosclerotic 
plaque gene signature in ACP tumours relative to control 
tissues (NES = 2.12, FDR < 0.001) (Fig. 9b). Together, 
these results suggest an activation of the inflammasomes 
in human ACP and identify cholesterol as a possible 
activator.
Fig. 5  Identification of the activation of the MAPK/ERK, TGFB and 
BMP signalling pathways in the ACP embryonic mouse model. Dou-
ble immunofluorescent staining on histological sections of neoplas-
tic pituitaries of the ACP embryonic mouse model at postnatal day 
1 (P1). Note the widespread expression of pERK1/2 in cells around 
the β-catenin-accumulating cell clusters, which show no expression of 
this marker. pSMAD3 and pSMAD1/5/9 staining is also predominant 
in cells surrounding the clusters, but occasionally weak staining is 
observed in some cluster cells (arrowheads). Scale bars 50 μm
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Fig. 6  Ex vivo inhibition of the MAPK/ERK pathway in mouse ACP 
results in decreased proliferation and increased apoptosis of tumour 
cells. Neoplastic pituitaries of the ACP embryonic mouse model were 
cultured in the presence of the MEK inhibitor trametinib (2 or 20 nM) 
or the vehicle control (DMSO) for 18 h. Following histological pro-
cessing, sections were immunostained against β-catenin and pERK1/2 
(readout of active MAPK/ERK pathway; a), Ki-67 (proliferation 
marker; b) and cleaved caspase-3 (apoptosis marker; c). Quantita-
tive analysis showing a significant dose-dependent reduction in Ki-67 
proliferative index (d; 20  nM) and an increase in apoptosis (e; 2 
and 20  nM) in trametinib-treated relative to vehicle-treated control. 
Kruskal–Wallis with Dunn’s post-test **p < 0.01; ***p < 0.001. Mean 
of 4.1 × 103 nuclei for each point. Scale bars 50 μm
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Fig. 7  Ex vivo inhibition of the MAPK/ERK pathway in human ACP 
results in decreased proliferation and increased apoptosis of tumour 
cells. Small pieces of three human ACP tumours were cultured in the 
presence of the MEK inhibitor trametinib (2 or 20 nM) or the vehi-
cle control (DMSO) for 18 h. Following histological processing, sec-
tions were immunostained against β-catenin and pERK1/2 (readout 
of active MAPK/ERK pathway; a), Ki-67 (proliferation marker; b) 
and cleaved caspase-3 (apoptosis marker; c). Quantitative analysis 
showing a significant dose-dependent reduction in Ki-67 proliferative 
index (d; 2 and 20 nM) and an increase in apoptosis (e; 20 nM) in 
trametinib-treated relative to vehicle-treated control. Kruskal–Wal-
lis with Dunn’s post-test **p < 0.01; ***p < 0.001. Mean of 1.6 × 104 
nuclei for each point. Scale bars 50 μm
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Discussion
In this study, we have revealed the molecular signatures 
of different compartments in human ACP, including the 
β-catenin-accumulating cell clusters, palisading epithe-
lium, glial tissue and the immune microenvironment. 
Through these analyses, we have identified and validated 
the expression of novel ACP genes, demonstrated the 
molecular similarities between human ACP and tooth 
development, revealed the MAPK/ERK pathway and 
inflammasome signalling as two novel targetable pathways 
and importantly, provided preliminary data supporting 
Fig. 8  Characterisation of the 
immune microenvironment in 
the solid component and cystic 
fluid of human ACP. a Immuno-
histochemistry showing infiltra-
tion of myeloid (CD68+ve) 
and lymphoid (CD3+ve) 
within human ACP tumour (T) 
and reactive glial tissue (G). 
CD68+ve and IBA1+ve immu-
nostaining is observed in close 
association with the cholesterol 
clefts (arrows). Likewise, 
immunohistochemistry against 
the chemokine CCL2 is detected 
near the cholesterol clefts. b 
The expression of the cytokines 
IL18, IL1B and IL10 corre-
late significantly with CD14 
expression, a marker preferen-
tially expressed in monocytes/
macrophages, in the 24 samples 
(ACP tumours and control tis-
sues) profiled by RNA-Seq. c 
Multiplex ELISA quantification 
of cytokine protein expression 
within the solid tumour (n = 8 
tumours; left) and cystic fluid 
(n = 10 samples; right). IL8, 
IL18, IL6 and IL1B are the 
highest expressed cytokines in 
the solid tumour. In the cystic 
fluid, levels of IL6 and IL8 are 
the highest, but all the other 
cytokines are also detected. 
For solid tumour values were 
normalised against total protein 
and for cystic fluid samples 
against volume. The blue dots 
represent the value obtained of 
each cytokine for each sample 
and the red dots represent the 
median. Scale bars 100 μm
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the use of MEK inhibitors against human ACP. A sche-
matic summary of the findings of this research is shown 
in Fig. 10.
We provide a rationale that explains the long-stand-
ing observation of the histological similarities of ACP 
tumours with tooth development and odontogenic tumours. 
We show that ACP β-catenin-accumulating clusters and 
the enamel knots of developing teeth are molecularly anal-
ogous structures, as are ACP palisading epithelium and 
dental inner enamel epithelium. These pairs share a molec-
ular signature and activate similar genetic programmes. 
Through the use of mouse models of ACP, we show that 
the expression of oncogenic β-catenin leading to the acti-
vation of the WNT pathway is sufficient to induce enamel 
epithelial/ameloblast-like gene expression and enamel 
knot-like cluster formation in Rathke’s pouch derivatives. 
Importantly, when the same degradation-resistant form of 
Ctnnb1 (Ctnnb1lox(ex3)) is activated in the enamel epithe-
lia under the control of the Krt14 or Sox2 promoters, the 
result is continuous tooth formation, with the presence of 
multiple enamel knots and with morphological similari-
ties to ACP [27, 58]. Of note, fully formed teeth including 
dentin are occasionally seen in human ACP [6, 42, 49].
Fig. 9  Activation of the inflammasomes underlies the ACP inflamma-
tory response. a Gene set enrichment plots showing that human ACP 
tumours are enriched for genes expressed by macrophages, chondro-
cytes and uterine muscle cells exposed to IL1B in culture conditions. 
b Gene set enrichment plots reveal a molecular signature of athero-
sclerotic plaques in human ACP. Results are based on data obtained 
from RNA-Seq profiles from whole ACP tumours and control tissues 
(fetal pituitaries and NFPA). c The levels of IL6, IL8 and TNFα pro-
tein correlate with levels of IL1B in human ACP cystic fluid (n = 10 
cystic fluid samples; determined by ELISA). NES normalised enrich-
ment score, FDR false discovery rate
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Analogous to the developing tooth, we highlight a com-
plex system of paracrine signalling occurring between tis-
sue compartments, centred on ACP clusters. We characterise 
the FGF, MAPK/ERK, TGFβ, BMP and EDAR signalling 
pathways in ACP. The importance for many of these genes 
and pathways has been functionally explored in the devel-
oping tooth, where their manipulation alters the number of 
teeth and/or their morphogenesis [20, 28, 38, 55, 57]. As the 
consequences of gene inactivation have been more exten-
sively studied in the tooth development field, it is plausible 
to speculate that this knowledge may inform on the genes/
pathways that may be more relevant in the pathogenesis of 
human ACP.
Illustrating this concept, we show that ex vivo MEK 
inhibition with trametinib results in decreased prolifera-
tion increased apoptosis in both mouse and human ACP. 
Likewise, individuals with Costello syndrome, a condition 
that results from germline activating mutations in HRAS 
leading to the over-activation of the MAPK/ERK pathway, 
show defective enamel mineralisation with increased num-
ber, proliferation and irregular orientation of ameloblasts 
[18]. This phenotype can be rescued by MEK inhibition in 
murine models of Costello syndrome [18]. We show that 
MAPK/ERK pathway inhibition ex vivo using trametinib 
is associated with decreased proliferation and increased 
apoptosis in both mouse and human ACP, suggesting that 
other pathways of importance during tooth development 
may also be relevant in the context of ACP pathogenesis. 
Future preclinical studies in both genetic and patient-
derived xenograft mouse models of ACP will assess the 
effects of trametinib treatment in tumour development.
Finally, we highlight that inflammasome activation 
may underlie the inflammation observed in human ACP, 
and identify that cholesterol crystals may be a potential 
inflammasome activator (Fig. 10). This finding could have 
important therapeutic consequences. Prevention of inflam-
masome activation by the use of IL1R inhibitors (e.g. 
anakinra) has been remarkably effective in several autoin-
flammatory diseases, most notably in cryopyrin-associated 
periodic syndromes (CAPS), gout and atherosclerotic dis-
ease [15, 44, 47, 52]. Inhibitors such as anakinra are used 
in routine clinical practice, including in paediatrics, and 
are known to cross the blood brain barrier and improve 
neuroinflammation in patients with severe CAPS [15, 44]. 
The ability to measure downstream cytokines e.g. IL6 and 
IL8 within cystic fluid offers an opportunity to develop 
biomarkers of therapy response to anakinra and other sim-
ilar drugs. In summary, we reveal a detailed molecular 
rationale underpinning the resemblance of ACP to tooth 
development and odontogenic tumours, and additionally, 
we provide evidence from preclinical testing of the use 
Fig. 10  Schematic summary of the findings. Molecular and histologi-
cal relationships between ACP pathogenesis and tooth development. 
The enamel knot and the β-catenin-accumulating clusters, which both 
have similar expression profiles and comparable histology, act as sig-
nalling hubs through the secretion of a several growth factors acting 
in an autocrine and/or paracrine manner on the surrounding cells, i.e. 
the enamel epithelium/dental mesenchyme in the forming tooth or 
the palisading epithelium, stellate reticulum and glial reactive tissue 
in ACP. Reciprocal signalling from surrounding tissues to the enamel 
knot and clusters is indicated by double-headed arrows. In the glial 
reactive tissue, cholesterol crystals activate the inflammasomes result-
ing in the secretion of IL1B, which in turn acts on the local immune 
effector cells to drive an inflammatory response
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of novel targeted therapies in ACP, opening the door for 
biologically driven studies in human patients.
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